Aberdeen Group plc Has $449.36 Million Holdings in Johnson & Johnson (NYSE:JNJ)

Aberdeen Group plc boosted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 39.0% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 2,708,599 shares of the company’s stock after purchasing an additional 760,488 shares during the quarter. Johnson & Johnson accounts for about 0.9% of Aberdeen Group plc’s holdings, making the stock its 17th biggest position. Aberdeen Group plc’s holdings in Johnson & Johnson were worth $449,357,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Highline Wealth Partners LLC grew its stake in Johnson & Johnson by 51.8% during the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock valued at $42,000 after acquiring an additional 86 shares in the last quarter. Stone House Investment Management LLC purchased a new position in Johnson & Johnson during the 1st quarter valued at about $47,000. von Borstel & Associates Inc. purchased a new position in Johnson & Johnson during the 1st quarter valued at about $49,000. Harvest Fund Management Co. Ltd purchased a new position in Johnson & Johnson during the 1st quarter valued at about $52,000. Finally, Capital A Wealth Management LLC purchased a new position in Johnson & Johnson during the 4th quarter valued at about $50,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Guggenheim reaffirmed a “neutral” rating and set a $167.00 target price (up previously from $164.00) on shares of Johnson & Johnson in a research note on Thursday, July 17th. Morgan Stanley boosted their price target on Johnson & Johnson from $171.00 to $176.00 and gave the company an “equal weight” rating in a research note on Thursday, July 17th. Leerink Partners cut Johnson & Johnson from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $169.00 to $153.00 in a research note on Tuesday, May 13th. Piper Sandler reissued an “overweight” rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Finally, Barclays boosted their price target on Johnson & Johnson from $165.00 to $176.00 and gave the company an “equal weight” rating in a research note on Thursday, July 17th. Nine equities research analysts have rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $174.50.

Johnson & Johnson Stock Up 0.3%

JNJ opened at $174.96 on Friday. The business has a 50 day moving average price of $160.85 and a 200 day moving average price of $158.16. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $175.72. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. The firm has a market cap of $421.37 billion, a P/E ratio of 18.71, a price-to-earnings-growth ratio of 2.22 and a beta of 0.41.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%. The firm had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. During the same period in the previous year, the company earned $2.82 EPS. The company’s revenue for the quarter was up 5.8% on a year-over-year basis. Research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be issued a dividend of $1.30 per share. The ex-dividend date is Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.0%. Johnson & Johnson’s payout ratio is 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.